NextCure, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for NXTC, updated each market day.
NXTC AI Sentiment
AI predicts NextCure, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About NextCure, Inc. Common Stock
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Sector
Exchange
Market Cap
$39,912,196
Cap Tier
Employees
40
Headquarters
BELTSVILLE, MD
Listed Since
May 9, 2019
Website
NXTC Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
NXTC Volatility
NextCure, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
